
Nephrogen
Nephrogen is a YC Summer 2020 (S20) company. Based in New York, NY, USA. Team of 1.
About Nephrogen
Summary
Nephrogen develops gene therapies for kidney and pancreatic diseases, two tissue types that existing genetic medicines cannot reliably reach. Its NeFIND platform uses AI and high-throughput in vivo screening to design adeno-associated viral delivery vehicles with tissue-specific tropism, producing candidates that are far more efficient and less immunogenic than current options. The platform replaces manual, low-yield delivery vehicle discovery and unlocks therapeutic approaches for diseases that affect tens of millions of Americans and have no approved gene-based treatments.
Go-to-market
Nephrogen is a Stanford spinout advancing its pipeline through preclinical research, with the NeFIND platform positioned to support internal therapeutic programs targeting kidney and pancreatic diseases.
From the Y Combinator listing
Curative gene therapies for kidney diseases
Nephrogen is a biotech company developing curative gene therapies for kidney and pancreatic diseases. Kidney disease affects 1 in 7 Americans (~50 million people), has no cure, and accounts for nearly 10% of the Medicare budget.
Facts
- Healthcare / Healthcare -> Therapeutics
- New York, NY, USA
- 1
- Active
- Early
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works